Nov 11, 2024
In the rapidly evolving field of oncology, novel CDK7 inhibitors are emerging as game-changers, challenging the status quo of cancer treatment. By specifically targeting CDK7, these innovative therapies not only halt cancer cell proliferation but also enhance the effectiveness of existing treatments. With the abili...
Read More...
Nov 04, 2024
Cyclin-dependent kinase 7 (CDK7) belongs to the CDK family of serine/threonine protein kinases and plays a crucial role in regulating the cell cycle and mRNA transcription. It is often overexpressed in various cancers, making it a promising target for cancer treatment due to its involvement in both transcription an...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper